Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 18:12:799.
doi: 10.3332/ecancer.2018.799. eCollection 2018.

The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima

Karoline Stenning-Persivale  1 , Maria Jose Savitzky Franco  1 , Alejandra Cordero-Morales  1 , José Cruzado-Burga  2 , Ebert Poquioma  2 , Edgar Díaz Nava  2 , Eduardo Payet  2
Affiliations

The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima

Karoline Stenning-Persivale et al. Ecancermedicalscience. .

Abstract

Introduction: The Mortality-Incidence Ratio complement [1 - MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima.

Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004-2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin's lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 - MIR] and total observed five-year survival for the selected cancers.

Results: Observed and estimated five-year survival determined by [1 - MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson's r coefficient for the correlation between [MIR - 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 - MIR] (X) captures the 96.82% of observed survival (Y).

Conclusion: The Mortality-Incidence Ratio complement [1 - MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima.

Keywords: Peru; cancer; cancer registries; incidence; mortality; mortality/incidence ratio; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. (a) Observed survival curves for the five most frequent cancers and (b) observed survival curves for the five remaining cancers.
Figure 2.
Figure 2.. Regression line of five-year observed survival on 1 – MIR.
See this image and copyright information in PMC

References

    1. World Health Organization. Ginebra, Suiza: World Health Organization; 2014. WHO reports on the International agency for Research on Cancer. World Cancer Report 2014.
    1. Instituto Nacional de Enfermedades Neoplásicas. Lima, Peru: 2006. Guías para la promoción de la salud orientada a la prevención y control del Cáncer.
    1. Asadzadeh Vostakolaei F, Karim-kos HE, Janssen-heijnen ML, et al. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011;21(5):573–577. doi: 10.1093/eurpub/ckq120. - DOI - PubMed
    1. Sunkara V, Hébert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 2015;121(10):1563–1569. doi: 10.1002/cncr.29228. - DOI - PMC - PubMed
    1. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015;385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9. - DOI - PMC - PubMed

LinkOut - more resources